Reinvigorated Antibiotics Pipeline Could Produce Four NMEs In 2014
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With two novel antibiotics approved and two more under review, 2014 is seeing the end of a long lean period for antibacterial R&D, helped by incentives like Qualified Infectious Disease Product designation. But only one candidate, Cubist’s ceftozolane/tazobactam, addresses the urgent need to target resistant Gram-negative bacteria.
You may also be interested in...
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
CDC’s Antibiotic-Resistance Battle Plan Emphasizes Preserving Current Drugs
Developing new drugs is only one of the four actions to prevent antibiotic resistance CDC calls for in a report that encourages “stewardship” of available therapies.
Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says
FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.